<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Virol J</journal-id><journal-id journal-id-type="iso-abbrev">Virol. J</journal-id><journal-title-group><journal-title>Virology Journal</journal-title></journal-title-group><issn pub-type="epub">1743-422X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4351832</article-id><article-id pub-id-type="publisher-id">242</article-id><article-id pub-id-type="doi">10.1186/s12985-015-0242-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Association of human papillomavirus 16 E6 variants with cervical carcinoma and precursor lesions in women from Southern Mexico</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ortiz-Ortiz</surname><given-names>Julio</given-names></name><address><email>julioortiz771210@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Alarc&#x000f3;n-Romero</surname><given-names>Luz del Carmen</given-names></name><address><email>luzdelcarmen14@gmail.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Jim&#x000e9;nez-L&#x000f3;pez</surname><given-names>Marco Antonio</given-names></name><address><email>marcoajl16@gmail.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Garz&#x000f3;n-Barrientos</surname><given-names>V&#x000ed;ctor Hugo</given-names></name><address><email>victhorgarzon@hotmail.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Calleja-Mac&#x000ed;as</surname><given-names>Itzel</given-names></name><address><email>itzel14@yahoo.com</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Barrera-Salda&#x000f1;a</surname><given-names>Hugo Alberto</given-names></name><address><email>habarrera@gmail.com</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Leyva-V&#x000e1;zquez</surname><given-names>Marco Antonio</given-names></name><address><email>leyvamarco13@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Illades-Aguiar</surname><given-names>Berenice</given-names></name><address><email>b.illadesaguiar@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Laboratorio de Biomedicina Molecular, Unidad Acad&#x000e9;mica de Ciencias Qu&#x000ed;mico Biol&#x000f3;gicas, Universidad Aut&#x000f3;noma de Guerrero, Chilpancingo, Guerrero M&#x000e9;xico </aff><aff id="Aff2"><label/>Laboratorio de Citopatolog&#x000ed;a, Unidad Acad&#x000e9;mica de Ciencias Qu&#x000ed;mico Biol&#x000f3;gicas, Universidad Aut&#x000f3;noma de Guerrero, Chilpancingo, Guerrero M&#x000e9;xico </aff><aff id="Aff3"><label/>Instituto Estatal de Cancerolog&#x000ed;a &#x0201c;Dr. Arturo Beltr&#x000e1;n Ortega&#x0201d;, Acapulco, Guerrero M&#x000e9;xico </aff><aff id="Aff4"><label/>Molecular Biology and Biochemistry, School of Biological Sciences, University of California Irvine, Irvine, CA USA </aff><aff id="Aff5"><label/>Departamento de Bioqu&#x000ed;mica y Medicina Molecular, Facultad de Medicina, Universidad Aut&#x000f3;noma de Nuevo Le&#x000f3;n, Monterrey, Nuevo Le&#x000f3;n M&#x000e9;xico </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>12</volume><elocation-id>29</elocation-id><history><date date-type="received"><day>9</day><month>10</month><year>2014</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Ortiz-Ortiz et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>HPV 16 is the cause of cervical carcinoma, but only a small fraction of women with HPV infection progress to this pathology. Besides persistent infection and HPV integration, several studies have suggested that HPV intratype variants may contribute to the development of cancer. The purpose of this study was to investigate the nucleotide variability and phylogenetically classify HPV 16 E6 variants circulating over a period of 16&#x000a0;years in women from Southern Mexico, and to analyze its association with precursor lesions and cervical carcinoma.</p></sec><sec><title>Methods</title><p>This study was conducted in 330 cervical DNA samples with HPV 16 from women who were residents of the State of Guerrero, located in Southern Mexico. According of cytological and/or histological diagnosis, samples were divided into the following four groups: no intraepithelial lesion (n&#x02009;=&#x02009;97), low-grade squamous intraepithelial lesion (n&#x02009;=&#x02009;123), high-grade squamous intraepithelial lesion (n&#x02009;=&#x02009;19) and cervical carcinoma (n&#x02009;=&#x02009;91). HPV 16 E6 gene was amplified, sequenced and aligned with reference sequence (HPV 16R) and a phylogenetic tree was constructed to identify and classify HPV 16 variants. Chi squared was used and data analysis and statistics were done with SPSS Statistics and STATA softwares.</p></sec><sec><title>Results</title><p>Twenty seven HPV 16 E6 variants were detected in women from Southern Mexico, 82.12% belonged to the EUR, 17.58% to AA1 and 0.3% to Afr2a sublineages. The most common was E-G350 (40%), followed by E-prototype (13.03%), E-C188/G350 (11.82%), AA-a (10.61%), AA-c (6.07%) and E-A176/G350 (5.15%). Eight new E6 variants were found and 2 of them lead to amino acid change: E-C183/G350 (I27T) and E-C306/G350 (K68T). The HPV 16 variant that showed the greatest risk of leading to the development of CC was AA-a (OR&#x02009;=&#x02009;69.01, CI&#x02009;=&#x02009;7.57-628.96), followed by E-A176/G350 (OR&#x02009;=&#x02009;39.82, CI&#x02009;=&#x02009;4.11-386.04), AA-c (OR&#x02009;=&#x02009;21.16, CI 2.59-172.56), E-G350 (OR&#x02009;=&#x02009;13.25, CI&#x02009;=&#x02009;2.02-87.12) and E-C188/G350 (OR&#x02009;=&#x02009;10.48, CI&#x02009;=&#x02009;1.39-78.92).</p></sec><sec><title>Conclusions</title><p>The variants more frequently found in women with cervical carcinoma are E-G350, AA-a, AA-c, E-C188/G350 and E-A176/G350. All of them are associated with the development of cervical carcinoma, however, AA-a showed the highest association. This study reinforces the proposal that HPV 16 AA-a is an oncogenic risk for cervical carcinoma progression in Mexico.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12985-015-0242-3) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HPV 16 variants</kwd><kwd>Cervical cancer</kwd><kwd>Precursor lesions</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Infection by high risk human papillomavirus (HR-HPV) is necessary for the development of cervical carcinoma (CC) [<xref ref-type="bibr" rid="CR1">1</xref>] and HPV 16 is the cause of more than half of CC worldwide [<xref ref-type="bibr" rid="CR2">2</xref>]. Only a small fraction of women with HPV infection may progress to cervical carcinoma; however, the factors that favor this progression are still poorly understood. Besides persistent infection and HPV integration [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>], several studies have suggested that HPV intratype variants may contribute to cancer development [<xref ref-type="bibr" rid="CR4">4</xref>-<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>Like other HR-HPV, HPV 16 has well preserved distinctive intratypic variants by geographical origin [<xref ref-type="bibr" rid="CR8">8</xref>], their global distribution and risk of cervical carcinoma appears to be dependent on the population [<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref>]. Its phylogeny reflects evolutionary divergence associated with human migration patterns, suggesting that they may have co-diversified as human populations expanded worldwide [<xref ref-type="bibr" rid="CR11">11</xref>]. HPV 16 variants have been classified into 4 major lineages and 9 sublineages based on common LCR and E6 single polymorphisms: (1) European-Asian (EAS), including European (EUR) and Asian (As) sublineages; (2) African 1 (AFR1), including Afr1a and Afr1b sublineages; (3) African 2 (AFR2), including Afr2a and Afr2b sublineages; and (4) Asian American/North American (AA/NA), including Asian American 1 (AA1), Asian American 2 (AA2) and North American (NA) sublineages [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Several reports have shown the presence of common polymorphisms that generate amino acid changes in the E6 oncoprotein, one of them is T350G, and is present in the four lineages. T350G causes a leucine to valine change (L83V), that leads to the split of the EUR sublineage into three classes, 350&#x000a0;T (prototype sequence), 350C and 350G. Other polymorphisms including A131G, G132C, C143G, G145T, G176A, T178G and C335T generate the amino acid changes R10G/I, Q14H/D, D25E/N, I27R and H78Y, respectively [<xref ref-type="bibr" rid="CR13">13</xref>]. It has been suggested that these polymorphisms and the subsequent amino acid changes in E6 HPV 16 variants may influence the persistence of HPV infection and its progression to cervical carcinoma [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR14">14</xref>-<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>Epidemiologic data shows that regions with high incidence of cervical carcinoma like Latin America, Africa and Asia, also have a high prevalence of sublineages AA and Af [<xref ref-type="bibr" rid="CR9">9</xref>]. Studies in Mexico have reported that persistent infection and risk of progression to cervical carcinoma is higher when HPV infection is caused by AA sub-lineages compared with EUR sublineages [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR19">19</xref>-<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>Social disparities like access to social security health care services, ethnic groups, residence and socioeconomic level are factors associated with cervical carcinoma development [<xref ref-type="bibr" rid="CR22">22</xref>]. The State of Guerrero, located in Southern Mexico, is the second poorest state in Mexico and a majority of inhabitants have a very low socioeconomic level. In this region, cervical carcinoma is the most common type of cancer in women and has the fourth highest mortality rate in the country with 12.5 deaths per 100,000 women, compared to the national mortality rate of 9.1 per 100,000 in 2008 [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>We have previously shown that HPV 16 was the most commonly identified HPV genotype in cervical carcinoma and high grade squamous intraepithelial lesions in women from the State of Guerrero. We studied a sample of HPV 16 positive women and found E and AA variants [<xref ref-type="bibr" rid="CR24">24</xref>]. It has been proposed that variants AA of HPV 16 are more oncogenic than E variants [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR25">25</xref>].</p><p>Knowing the regional variants of HPV 16 is of great value for evolutionary, phylogenetic, epidemiological and biological analysis [<xref ref-type="bibr" rid="CR13">13</xref>]. To further analyze the regional variants of HPV 16, the aim of this study was to investigate the nucleotide variability and phylogenetically classify HPV 16 E6 variants circulating over a period of 16&#x000a0;years in the Southern Mexican population, and to analyze its association with the whole spectrum of disease from no intraepithelial lesion in cervical epithelium to cervical carcinoma.</p><p>The most dominant HPV variants were detected in low and high-grade squamous intraepithelial lesion, cervical carcinoma and no intraepithelial lesion, and 8 novel HPV 16 variants were found. An association between E-G350, E-A176/G350, E-C188/G350, AA-a and AA-c variants and the risk of developing cervical carcinoma was shown in this study.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>HPV 16 E6 variants and phylogenetic analysis</title><p>The variant analysis for the E6 gene was carried out in 330 HPV16 samples from all study groups. Using the HPV 16 R (Los Alamos National Laboratory, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NC_001526.2">http://www.ncbi.nlm.nih.gov/nuccore/NC_001526.2</ext-link>) as a reference sequence, a total of 27 variants were detected, 8 of them were new. Sequence analysis showed substitution in 29 nucleotides located between positions 104 and 559 in the E6 sequence with a predicted amino acid change (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p><bold>Phylogenetic classification, nucleotide sequence variations and frequency of HPV-16 E6 variants identified in women from Southern Mexico</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Variants</bold>
</th><th colspan="26">
<bold>HPV 16 E6 nucleotide position</bold>
</th><th>
<bold>Predicted amino acid change E6 protein (151 aa form)</bold>
</th><th colspan="2">
<bold>Frequency</bold>
</th></tr></thead><tbody><tr valign="top"><td/><td>
<bold>109</bold>
</td><td>
<bold>110</bold>
</td><td>
<bold>131</bold>
</td><td>
<bold>132</bold>
</td><td>
<bold>143</bold>
</td><td>
<bold>145</bold>
</td><td>
<bold>176</bold>
</td><td>
<bold>182</bold>
</td><td>
<bold>183</bold>
</td><td>
<bold>185</bold>
</td><td>
<bold>188</bold>
</td><td>
<bold>189</bold>
</td><td>
<bold>256</bold>
</td><td>
<bold>257</bold>
</td><td>
<bold>271</bold>
</td><td>
<bold>286</bold>
</td><td>
<bold>289</bold>
</td><td>
<bold>306</bold>
</td><td>
<bold>310</bold>
</td><td>
<bold>335</bold>
</td><td>
<bold>350</bold>
</td><td>
<bold>403</bold>
</td><td>
<bold>424</bold>
</td><td>
<bold>442</bold>
</td><td>
<bold>532</bold>
</td><td>
<bold>535</bold>
</td><td/><td>
<bold>N=330</bold>
</td><td>
<bold>%</bold>
</td></tr><tr valign="top"><td>HPV 16R</td><td>T</td><td>C</td><td>A</td><td>G</td><td>C</td><td>G</td><td>G</td><td>A</td><td>T</td><td>T</td><td>G</td><td>A</td><td>C</td><td>A</td><td>T</td><td>T</td><td>A</td><td>A</td><td>C</td><td>C</td><td>T</td><td>A</td><td>A</td><td>A</td><td>A</td><td>A</td><td/><td/><td/></tr><tr valign="top"><td colspan="30">Lineage EAS/Sublineage EUR</td></tr><tr valign="top"><td>Class E-T350</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>
<bold>51</bold>
</td><td>
<bold>15.45%</bold>
</td></tr><tr valign="top"><td>E-Prototype</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>No change</td><td>43</td><td>13.03%</td></tr><tr valign="top"><td>E-G131</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>R10G</td><td>8</td><td>2.42%</td></tr><tr valign="top"><td>Class E-G350</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>
<bold>220</bold>
</td><td>
<bold>66.67%</bold>
</td></tr><tr valign="top"><td>E-G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>L83V</td><td>132</td><td>40.00%</td></tr><tr valign="top"><td>E-C109/G350</td><td>c</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>L83V</td><td>6</td><td>1.82%</td></tr><tr valign="top"><td>E-G110/G350</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>Q3E/L83V</td><td>2</td><td>0.61%</td></tr><tr valign="top"><td>E-G131/G350</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>R10G/L83V</td><td>2</td><td>0.61%</td></tr><tr valign="top"><td>E-G131/C188/G350</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>C</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>R10G/E29Q/L83V</td><td>2</td><td>0.61%</td></tr><tr valign="top"><td>E-A176/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>A</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>D25N/L83V</td><td>17</td><td>5.15%</td></tr><tr valign="top"><td>**E-A176/G424/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>A</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>g</td><td>-</td><td>-</td><td>-</td><td>D25N/L83V</td><td>1</td><td>0.30%</td></tr><tr valign="top"><td>E-T182/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>T</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>I27L/L83V</td><td>4</td><td>1.21%</td></tr><tr valign="top"><td>E-C182/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>C</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>I27L/L83V</td><td>2</td><td>0.61%</td></tr><tr valign="top"><td>**E-C183/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>
<italic>C</italic>
</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>I27T/L83V</td><td>3</td><td>0.91%</td></tr><tr valign="top"><td>E-G185/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>L28V/L83V</td><td>2</td><td>0.61%</td></tr><tr valign="top"><td>E-A188/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>A</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>E29K/L83V</td><td>1</td><td>0.30%</td></tr><tr valign="top"><td>E-C188/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>C</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>E29Q/L83V</td><td>39</td><td>11.82%</td></tr><tr valign="top"><td>**E-C188/G310/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>C</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>E29Q/F69L/L83V</td><td>2</td><td>0.61%</td></tr><tr valign="top"><td>**E-G189/T256/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>t</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>E29G/L83V</td><td>1</td><td>0.30%</td></tr><tr valign="top"><td>E-G257/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>I52L/L83V</td><td>1</td><td>0.30%</td></tr><tr valign="top"><td>**E-C306/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>
<italic>C</italic>
</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>K68T/L83V</td><td>1</td><td>0.30%</td></tr><tr valign="top"><td>E-C442/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>C</td><td>-</td><td>-</td><td>L83V/E113D</td><td>1</td><td>0.30%</td></tr><tr valign="top"><td>**G535/G350</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>
<italic>g</italic>
</td><td>L83V</td><td>1</td><td>0.30%</td></tr><tr valign="top"><td colspan="30">Lineage AA/NA/Sublineage AA1</td></tr><tr valign="top"><td>Class AA-a</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>
<bold>36</bold>
</td><td>
<bold>10.91%</bold>
</td></tr><tr valign="top"><td>AA-a</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>T</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>a</td><td>g</td><td>-</td><td>-</td><td>T</td><td>G</td><td>-</td><td>-</td><td>-</td><td>g</td><td>-</td><td>Q14H/H78Y/L83V</td><td>35</td><td>10.61%</td></tr><tr valign="top"><td>**AA-a/C188</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>T</td><td>-</td><td>-</td><td>-</td><td>-</td><td>C</td><td>-</td><td>-</td><td>-</td><td>-</td><td>a</td><td>g</td><td>-</td><td>-</td><td>T</td><td>G</td><td>-</td><td>-</td><td>-</td><td>g</td><td>-</td><td>Q14H/E29Q/H78Y/L83V</td><td>1</td><td>0.30%</td></tr><tr valign="top"><td>Class AA-c</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>
<bold>22</bold>
</td><td>
<bold>6.67%</bold>
</td></tr><tr valign="top"><td>AA-c</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>T</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>a</td><td>g</td><td>-</td><td>-</td><td>T</td><td>G</td><td>-</td><td>-</td><td>-</td><td>g</td><td>-</td><td>Q14H/I27R/H78Y/L83V</td><td>20</td><td>6.07%</td></tr><tr valign="top"><td>**AA-c/G185</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>T</td><td>-</td><td>-</td><td>G</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>a</td><td>a</td><td>-</td><td>-</td><td>T</td><td>G</td><td>-</td><td>-</td><td>-</td><td>g</td><td>-</td><td>Q14H/I27R/L28V/H78Y/L83V</td><td>1</td><td>0.30%</td></tr><tr valign="top"><td>AA-c/C271</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>T</td><td>-</td><td>-</td><td>G</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>c</td><td>a</td><td>g</td><td>-</td><td>-</td><td>T</td><td>G</td><td>-</td><td>-</td><td>-</td><td>g</td><td>-</td><td>Q14H/I27R/H78Y/L83V</td><td>1</td><td>0.30%</td></tr><tr valign="top"><td colspan="30">Lineage AFR2/Sublineage Afr2a</td></tr><tr valign="top"><td>Class Af2-a</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>
<bold>1</bold>
</td><td>
<bold>0.30%</bold>
</td></tr><tr valign="top"><td>Af2-a/C109/G403</td><td>c</td><td>-</td><td>-</td><td>T</td><td>G</td><td>T</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>a</td><td>g</td><td>-</td><td>-</td><td>T</td><td>-</td><td>g</td><td>-</td><td>-</td><td>-</td><td>-</td><td>R10I/Q14D/H78Y</td><td>1</td><td>0.30%</td></tr></tbody></table><table-wrap-foot><p>HPV 16 R: reference sequence. Predicted amino acid change: the amino acid numeration was done using the 151 amino acid E6 oncoprotein form as reference. Capital letters indicate polymorphisms that produce amino acid change. Lower-case letters indicate silent mutations. &#x02013; Indicate no polymorphism. Italic letters indicate new polymorphisms. Italic capital letters indicate amino acid change. **Indicate new variants.</p></table-wrap-foot></table-wrap></p><p>The phylogenetic analysis showed that the E6 variants found belong to EUR, AA1 and Afr2a sublineages. Six of the 8 novel variants were related to variants of the EUR sublineages, and 2 to variants of the AA1 sublineage (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Phylogenetic tree based in E6 variations of HPV 16.</bold> To classify the newly identified variants, their phylogenetic relationship with previously reported variants were determined, by constructing a phylogenetic tree based on E6 sequences found in Southern Mexico. The new variants are underlined. The tree is drawn to scale with branch lengths measured in the number of substitutions per site. The analysis involved 27 nucleotide sequences. All positions containing gaps and missing data were eliminated. There were a total of 456 positions in the final dataset. Analyses were conducted in MEGA5.2 [<xref ref-type="bibr" rid="CR43">43</xref>].</p></caption><graphic xlink:href="12985_2015_242_Fig1_HTML" id="MO1"/></fig></p><p>The phylogenetic classification of the E6 variants showed that the majority (82.12%) belonged to the EUR sublineage, followed by AA1 (17.58%) and Afr2a (0.3%) sublineages. From sublineage EUR, 15.45% was class E-T350 which includes E-Prototype (13.03%), and 66.67% was class E-G350 finding 19 subclasses. From sublineage AA1, AA-a class was the most frequent (10.91%) followed by AA-c class (6.67%). From the 27 variants found in this study, the most common E6 variant was E-G350 (40%), followed by E-prototype (13.03%), E-C188/G350 (11.82%), AA-a (10.61%), AA-c (6.07%) and E-A176/G350 (5.15%). The 8 novel variants are subclasses, 6 are subclasses of class G-350, one is subclass of class AA-a and the last one is subclass of class AA-c (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). E-C183/G350, E-C306/G350 and E-G535/G350 show polymorphisms that so far have not been reported, E-C183/G350 leads to the amino acid change I27T, E-C306/G350 changes K68T and E-G535/G350 does not lead to any amino acid change (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec4"><title>HPV 16 E6 variants in cervical carcinoma and precursor lesions</title><p>A total of 330 samples with HPV16 were analyzed. The histology of the 91 cervical carcinoma identified 76 (83.5%) as squamous cell carcinoma (SCC), 13 (14.3%) as adenocarcinoma (ADC) and 2 (2.2%) as other epithelial tumors. The majority of cases of cervical carcinomas were found in the FIGO stage IIB (34%). Additionally, 19 samples were HSIL, 123 LSIL and 97 with non-IL (11 with inflammation and 86 with normal Pap smears).</p><p>HPV 16 AA variants were more common in ADC (46.15%) than in SCC (30.27%). AA-a variants increased their frequency according to the degree of evolution of cervical lesion: 38.46% in ADC, 15.79% in SCC, 15.79% in HSIL, 8.94% in LSIL and 3.09% in non-IL. HPV 16 E variants were the most common in SCC (69.75%), HSIL (78.94%), LSIL (87.79%) and non-IL (89.69%). HPV 16 E-G350 class was the most frequent in all groups, E-Prototype, on the other hand, was not detected in ADC and other epithelial tumors, and only 2.63% of SCC, 5.26% of HSIL, 18.7% of LSIL and 17.53% of non-IL (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The Af variants were not found in any cervical carcinoma.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Distribution of HPV 16 E6 variants for diagnostic category</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Variant</bold>
</th><th>
<bold>Non-IL N=97</bold>
</th><th>
<bold>LSIL N=123</bold>
</th><th>
<bold>HSIL N=19</bold>
</th><th>
<bold>SCC N=76</bold>
</th><th>
<bold>ADC N=13</bold>
</th><th>
<bold>Other Epithelial Tumor N=2</bold>
</th><th>
<bold>Cervical carcinoma N=91</bold>
</th><th>
<bold>Total N=330</bold>
</th></tr></thead><tbody><tr valign="top"><td>E variants</td><td>
<bold>87 (89.69%)</bold>
</td><td>
<bold>108 (87.79%)</bold>
</td><td>
<bold>15 (78.94%)</bold>
</td><td>
<bold>53 (69.75%)</bold>
</td><td>
<bold>7 (53.84%)</bold>
</td><td>
<bold>1 (50.0%)</bold>
</td><td>
<bold>61 (67.05%)</bold>
</td><td>
<bold>271 (82.12%)</bold>
</td></tr><tr valign="top"><td>Class E-T350</td><td>
<bold>23 (23.72%)</bold>
</td><td>
<bold>23 (18.7%)</bold>
</td><td>
<bold>1 (5.26%)</bold>
</td><td>
<bold>4 (5.26%)</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>4 (4.4%)</bold>
</td><td>
<bold>51 (15.45%)</bold>
</td></tr><tr valign="top"><td>E-Prototype</td><td>17 (17.53%)</td><td>23 (18.7%)</td><td>1 (5.26%)</td><td>2 (2.63%)</td><td>-</td><td>-</td><td>2 (2.2%)</td><td>43 (13.03%)</td></tr><tr valign="top"><td>E-G131</td><td>6 (6.19%)</td><td>-</td><td>-</td><td>2 (2.63%)</td><td>-</td><td>-</td><td>2 (2.2%)</td><td>8 (2.42%)</td></tr><tr valign="top"><td>Class E-G350</td><td>
<bold>64 (65.97%)</bold>
</td><td>
<bold>85 (69.09%)</bold>
</td><td>
<bold>14 (73.68%)</bold>
</td><td>
<bold>49 (64.49%)</bold>
</td><td>
<bold>7 (53.84%)</bold>
</td><td>
<bold>1 (50.0%)</bold>
</td><td>
<bold>57 (62.65%)</bold>
</td><td>
<bold>220 (66.67%)</bold>
</td></tr><tr valign="top"><td>E-G350</td><td>39 (40.21%)</td><td>56 (45.53%)</td><td>6 (31.58%)</td><td>28 (36. 84%)</td><td>3 (23.08%)</td><td>-</td><td>31 (34.07%)</td><td>132 (40.00%)</td></tr><tr valign="top"><td>E-C109/G350</td><td>-</td><td>3 (2.44%)</td><td>1 (5.26%)</td><td>2 (2.63%)</td><td>-</td><td>-</td><td>2 (2.2%)</td><td>6 (1.82%)</td></tr><tr valign="top"><td>E-G110/G350</td><td>1 (1.03%)</td><td>1 (0.81%)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>2 (0.61%)</td></tr><tr valign="top"><td>E-G131/G350</td><td>1 (1.03%)</td><td>-</td><td>-</td><td>1 (1.32%)</td><td>-</td><td>-</td><td>1 (1.1%)</td><td>2 (0.61%)</td></tr><tr valign="top"><td>E-G131/C188/G350</td><td>1 (1.03%)</td><td>1 (0.81%)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>2 (0.61%)</td></tr><tr valign="top"><td>E-A176/G350</td><td>3 (3.09%)</td><td>5 (4.07%)</td><td>1 (5.26%)</td><td>5 (6.58%)</td><td>2 (15.38%)</td><td>1 (50.0%)</td><td>8 (8.79%)</td><td>17 (5.15%)</td></tr><tr valign="top"><td>**E-A176/G424/G350</td><td>-</td><td>-</td><td>-</td><td>1 (1.32%)</td><td>-</td><td>-</td><td>1 (1.1%)</td><td>1 (0.30%)</td></tr><tr valign="top"><td>E-T182/G350</td><td>-</td><td>1 (0.81%)</td><td>1 (5.26%)</td><td>2 (2.63%)</td><td>-</td><td>-</td><td>2 (2.2%)</td><td>4 (1.21%)</td></tr><tr valign="top"><td>E-C182/G350</td><td>1 (1.03%)</td><td>1 (0.81%)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>2 (0.61%)</td></tr><tr valign="top"><td>**E-C183/G350</td><td>3 (3.09%)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>3 (0.91%)</td></tr><tr valign="top"><td>E-G185/G350</td><td>1 (1.03%)</td><td>-</td><td>-</td><td>1 (1.32%)</td><td>-</td><td>-</td><td>1 (1.1%)</td><td>2 (0.61%)</td></tr><tr valign="top"><td>E-A188/G350</td><td>-</td><td>-</td><td>-</td><td>1 (1.32%)</td><td>-</td><td>-</td><td>1 (1.1%)</td><td>1 (0.30%)</td></tr><tr valign="top"><td>E-C188/G350</td><td>11 (11.34%)</td><td>13 (10.57%)</td><td>5 (26.32%)</td><td>8 (10.53%)</td><td>2 (15.38%)</td><td>-</td><td>10 (10.99%)</td><td>39 (11.82%)</td></tr><tr valign="top"><td>**E-C188/G310/G350</td><td>1 (1.03%)</td><td>1 (0.81%)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>2 (0.61%)</td></tr><tr valign="top"><td>**E-G189/T256/G350</td><td>-</td><td>1 (0.81%)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>1 (0.30%)</td></tr><tr valign="top"><td>E-G257/G350</td><td>-</td><td>1 (0.81%)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>1 (0.30%)</td></tr><tr valign="top"><td>**E-C306/G350</td><td>1 (1.03%)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>1 (0.30%)</td></tr><tr valign="top"><td>E-C442/G350</td><td>1 (1.03%)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>1 (0.30%)</td></tr><tr valign="top"><td>**G535/G350</td><td>-</td><td>1 (0.81%)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>1 (0.30%)</td></tr><tr valign="top"><td>AA variants</td><td>
<bold>10 (10.31%)</bold>
</td><td>
<bold>14 (11.38%)</bold>
</td><td>
<bold>4 (21.05%)</bold>
</td><td>
<bold>23 (30.27%)</bold>
</td><td>
<bold>6 (46.15%)</bold>
</td><td>
<bold>1 (50.0%)</bold>
</td><td>
<bold>30 (32.97%)</bold>
</td><td>
<bold>58 (17.58%)</bold>
</td></tr><tr valign="top"><td>Class AA-a</td><td>
<bold>4 (4.12%)</bold>
</td><td>
<bold>11 (8.94%)</bold>
</td><td>
<bold>3 (15.79%)</bold>
</td><td>
<bold>12 (15.79%)</bold>
</td><td>
<bold>5 (38.46%)</bold>
</td><td>
<bold>1 (50.0%)</bold>
</td><td>
<bold>18 (19.78%)</bold>
</td><td>
<bold>36 (10.91%)</bold>
</td></tr><tr valign="top"><td>AA-a</td><td>3 (3.09%)</td><td>11 (8.94%)</td><td>3 (15.79%)</td><td>12 (15.79%)</td><td>5 (38.46 %)</td><td>1 (50.0%)</td><td>18 (19.78%)</td><td>35 (10.61%)</td></tr><tr valign="top"><td>**AA-a/C188</td><td>1 (1.03%)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>1 (0.30%)</td></tr><tr valign="top"><td>Class AA-c</td><td>
<bold>6 (6.19%)</bold>
</td><td>
<bold>3 (2.44%)</bold>
</td><td>
<bold>1 (5.26%)</bold>
</td><td>
<bold>11 (14.48%)</bold>
</td><td>
<bold>1 (7.69%)</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>12 (13.19%)</bold>
</td><td>
<bold>22 (6.67%)</bold>
</td></tr><tr valign="top"><td>AA-c</td><td>6 (6.19%)</td><td>3 (2.44%)</td><td>1 (5.26%)</td><td>9 (11.84%)</td><td>1 (7.69%)</td><td>-</td><td>10 (10.99%)</td><td>20 (6.07%)</td></tr><tr valign="top"><td>**AA-c/G185</td><td>-</td><td>-</td><td>-</td><td>1 (1.32%)</td><td>-</td><td>-</td><td>1 (1.1%)</td><td>1 (0.30%)</td></tr><tr valign="top"><td>AA-c/C271</td><td>-</td><td>-</td><td>-</td><td>1 (1.32%)</td><td>-</td><td>-</td><td>1 (1.1%)</td><td>1 (0.30%)</td></tr><tr valign="top"><td>Af variants</td><td>
<bold>-</bold>
</td><td>
<bold>1 (0.81%)</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>1 (0.30%)</bold>
</td></tr><tr valign="top"><td>Class Af2-a</td><td>
<bold>-</bold>
</td><td>
<bold>1 (0.81%)</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>-</bold>
</td><td>-</td><td>
<bold>1 (0.30%)</bold>
</td></tr><tr valign="top"><td>Af2-a/C109/G403</td><td>-</td><td>1 (0.81%)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>1 (0.30%)</td></tr></tbody></table><table-wrap-foot><p>-,Indicate that the variant was not found.</p></table-wrap-foot></table-wrap></p><p>Associations between the five most frequent HPV 16 E6 variants and LSIL, HSIL and cervical carcinoma were assessed (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), using the HPV 16 E-Prototype as a reference. The 5 variants analyzed showed significant association with CC, but only AA-a variant showed significant association with HSIL. The HPV 16 variant that showed the most risk of developing CC was AA-a (OR&#x02009;=&#x02009;69.01, CI&#x02009;=&#x02009;7.57-628.96), followed by E-A176/G350 (OR&#x02009;=&#x02009;39.82, CI&#x02009;=&#x02009;4.11-386.04), AA-c (OR&#x02009;=&#x02009;21.16, CI 2.59-172.56), E-G350 (OR&#x02009;=&#x02009;13.25, CI&#x02009;=&#x02009;2.02-87.12) and E-C188/G350 (OR&#x02009;=&#x02009;10.48, CI&#x02009;=&#x02009;1.39-78.92).<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>The most common HPV 16 E6 variants in women from Southern Mexico and risk of cervical carcinoma</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Variants</bold>
</th><th>
<bold>Non-IL N (%)</bold>
</th><th>
<bold>LSIL N (%)</bold>
</th><th>
<bold>OR (CI 95%) P</bold>
</th><th>
<bold>HSIL N (%)</bold>
</th><th>
<bold>OR (CI 95%) P</bold>
</th><th>
<bold>SCC N (%)</bold>
</th><th>
<bold>OR (CI 95%) p</bold>
</th><th>
<bold>ADC N (%)</bold>
</th><th>
<bold>OR (CI 95%) P</bold>
</th><th>
<bold>Other epithelial tumor N (%)</bold>
</th><th>
<bold>Cervical carcinoma N (%)</bold>
</th><th>
<bold>OR (CI 95%) P</bold>
</th></tr></thead><tbody><tr valign="top"><td>Class E-T350<sup>a</sup>
</td><td>
<bold>23 (23.71%)</bold>
</td><td>
<bold>23 (18.7%)</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>1 (5.26%)</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>4 (5.26%)</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>0 (0%)</bold>
<sup><bold>b</bold></sup>
</td><td>
<bold>-</bold>
</td><td>
<bold>0 (0.0%)</bold>
</td><td>
<bold>4 (4.40%)</bold>
</td><td>
<bold>-</bold>
</td></tr><tr valign="top"><td>E-Prototype</td><td>17 (17.53%)</td><td>23 (18.7%)</td><td>1*</td><td>1 (5.26%)</td><td>1*</td><td>2 (2.63%)</td><td>1*</td><td>0 (0%)<sup>b</sup>
</td><td>1*</td><td>-</td><td>2 (2.2%)</td><td>1*</td></tr><tr valign="top"><td rowspan="3">Class E-G350</td><td rowspan="3">
<bold>64 (65.98%)</bold>
</td><td rowspan="3">
<bold>85 (69.11%)</bold>
</td><td>
<bold>0.97</bold>
</td><td/><td>
<bold>3.73</bold>
</td><td/><td>
<bold>12.66</bold>
</td><td/><td>
<bold>2.42</bold>
</td><td/><td/><td>
<bold>14.12</bold>
</td></tr><tr valign="top"><td>
<bold>0.47-1.99</bold>
</td><td>
<bold>14 (73.68%)</bold>
</td><td>
<bold>0.46-30.44</bold>
</td><td>
<bold>49 (64.47%)</bold>
</td><td>
<bold>1.89-84.92</bold>
</td><td>
<bold>7 (53.85%)</bold>
</td><td>
<bold>0.25-</bold>&#x0221e;</td><td>
<bold>1 (50.0%)</bold>
</td><td>
<bold>57 (62.65%)</bold>
</td><td>
<bold>2.19-90.97</bold>
</td></tr><tr valign="top"><td>
<bold>0.94</bold>
</td><td/><td>
<bold>0.22</bold>
</td><td/><td>
<bold>0.009</bold>
</td><td/><td>
<bold>0.44</bold>
</td><td/><td/><td>
<bold>0.005</bold>
</td></tr><tr valign="top"><td rowspan="3">E-G350</td><td rowspan="3">39 (40.21%)</td><td rowspan="3">56 (45.53%)</td><td>1.01</td><td/><td>2.58</td><td/><td>12.56</td><td/><td>1.74</td><td/><td/><td>13.25</td></tr><tr valign="top"><td>0.47-2.17</td><td>6 (31.58%)</td><td>0.29-23.17</td><td>28 (36.84%)</td><td>1.84-85.86</td><td>3 (23.08%)</td><td>0.15-&#x0221e;</td><td>-</td><td>31 (34.07%)</td><td>2.02-87.12</td></tr><tr valign="top"><td>0.98</td><td/><td>0.39</td><td/><td>0.010</td><td/><td>0.65</td><td/><td/><td>0.007</td></tr><tr valign="top"><td rowspan="3">E-A176/G350</td><td rowspan="3">3 (3.09%)</td><td rowspan="3">5 (4.07%)</td><td>1.49</td><td/><td>5.82</td><td/><td>24.79</td><td/><td>12.62</td><td/><td/><td>39.82</td></tr><tr valign="top"><td>0.31-7.23</td><td>1 (5.26%)</td><td>0.28-121.37</td><td>5 (6.58%)</td><td>2.33-263.35</td><td>2 (15.38%)</td><td>0.79-&#x0221e;</td><td>1 (50.0%)</td><td>8 (8.79%)</td><td>4.11-386.04</td></tr><tr valign="top"><td>0.62</td><td/><td>0.26</td><td/><td>0.008</td><td/><td>0.07</td><td/><td/><td>0.001</td></tr><tr valign="top"><td rowspan="3">E-C188/G350</td><td rowspan="3">11 (11.34%)</td><td rowspan="3">13 (10.57%)</td><td>1.0</td><td/><td>7.91</td><td/><td>8.56</td><td/><td>3.05</td><td/><td/><td>10.48</td></tr><tr valign="top"><td>0.35-2.84</td><td>5 (26.32%)</td><td>0.81-77.58</td><td>8 (10.53%)</td><td>1.07-68.26</td><td>2 (15.38%)</td><td>0.23-&#x0221e;</td><td>-</td><td>10 (10.99%)</td><td>1.39-78.92</td></tr><tr valign="top"><td>0.99</td><td/><td>0.08</td><td/><td>0.043</td><td/><td>0.40</td><td/><td/><td>0.023</td></tr><tr valign="top"><td rowspan="3">Class AA-a</td><td rowspan="3">
<bold>4 (4.12%)</bold>
</td><td rowspan="3">
<bold>11 (8.94%)</bold>
</td><td>
<bold>2.18</bold>
</td><td/><td>
<bold>12.65</bold>
</td><td/><td>
<bold>35.21</bold>
</td><td/><td>
<bold>21.24</bold>
</td><td/><td/><td>
<bold>54.51</bold>
</td></tr><tr valign="top"><td>
<bold>0.58-8.17</bold>
</td><td>
<bold>3 (15.79%)</bold>
</td><td>
<bold>1.02-156.20</bold>
</td><td>
<bold>12 (15.79%)</bold>
</td><td>
<bold>3.87-320.39</bold>
</td><td>
<bold>5 (38.46%)</bold>
</td><td>
<bold>1.75-</bold>&#x0221e;</td><td>
<bold>1 (50.0%)</bold>
</td><td>
<bold>18 (19.78%)</bold>
</td><td>
<bold>6.36-467.62</bold>
</td></tr><tr valign="top"><td>
<bold>0.25</bold>
</td><td/><td>
<bold>0.048</bold>
</td><td/><td>
<bold>0.002</bold>
</td><td/><td>
<bold>0.016</bold>
</td><td/><td/><td>
<bold>0.000</bold>
</td></tr><tr valign="top"><td rowspan="3">AA-a</td><td rowspan="3">3 (3.09%)</td><td rowspan="3">11 (8.94%)</td><td>3.08</td><td/><td>17.40</td><td/><td>43.73</td><td/><td>26.69</td><td/><td/><td>69.01</td></tr><tr valign="top"><td>0.73-13.04</td><td>3 (15.79%)</td><td>1.32-229.60</td><td>12 (15.79%)</td><td>4.55-420.56</td><td>5 (38.46%)</td><td>2.10-&#x0221e;</td><td>1 (50.0%)</td><td>18 (19.78%)</td><td>7.57-628.96</td></tr><tr valign="top"><td>0.13</td><td/><td>0.03</td><td/><td>0.001</td><td/><td>0.01</td><td/><td/><td>0.000</td></tr><tr valign="top"><td rowspan="3">Class AA-c</td><td rowspan="3">
<bold>6 (6.19%)</bold>
</td><td rowspan="3">
<bold>3 (2.44%)</bold>
</td><td>
<bold>0.44</bold>
</td><td/><td>
<bold>2.79</bold>
</td><td/><td>
<bold>24.46</bold>
</td><td/><td>
<bold>3.01</bold>
</td><td/><td/><td>
<bold>25.28</bold>
</td></tr><tr valign="top"><td>
<bold>0.10-2.06</bold>
</td><td>
<bold>1 (5.26%)</bold>
</td><td>
<bold>0.15-52.20</bold>
</td><td>
<bold>11 (14.47%)</bold>
</td><td>
<bold>2.89-207.12</bold>
</td><td>
<bold>1 (7.69%)</bold>
</td><td>
<bold>0.15-</bold>&#x0221e;</td><td>
<bold>-</bold>
</td><td>
<bold>12 (13.19%)</bold>
</td><td>
<bold>3.12-204.74</bold>
</td></tr><tr valign="top"><td>
<bold>0.30</bold>
</td><td/><td>
<bold>0.49</bold>
</td><td/><td>
<bold>0.003</bold>
</td><td/><td>
<bold>0.47</bold>
</td><td/><td/><td>
<bold>0.002</bold>
</td></tr><tr valign="top"><td rowspan="3">AA-c</td><td rowspan="3">6 (6.19%)</td><td rowspan="3">3 (2.44%)</td><td>0.46</td><td/><td>2.93</td><td/><td>19.97</td><td/><td>2.99</td><td/><td/><td>21.16</td></tr><tr valign="top"><td>0.10-2.15</td><td>1 (5.26%)</td><td>0.16-54.90</td><td>9 (11.84%)</td><td>2.34-170.25</td><td>1 (7.69%)</td><td>0.15-&#x0221e;</td><td>-</td><td>10 (10.99%)</td><td>2.59-172.56</td></tr><tr valign="top"><td>0.32</td><td/><td>0.47</td><td/><td>0.006</td><td/><td>0.47</td><td/><td/><td>0.004</td></tr><tr valign="top"><td>Class Af2-a</td><td>
<bold>0 (0%)</bold>
</td><td>
<bold>1 (0.81%)</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>0 (0%)</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>0 (0%)</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>0 (0%)</bold>
</td><td>
<bold>-</bold>
</td><td>
<bold>0 (0%)</bold>
</td><td>
<bold>0 (0%)</bold>
</td><td>
<bold>-</bold>
</td></tr></tbody></table><table-wrap-foot><p>*,Indicate reference category (E-Prototype).</p><p>
<sup>a</sup> ,OR was not calculated for E-T350 class because it includes reference category (E-Prototype).</p><p>
<sup>b</sup>,To calculate OR and CI in ADC an artificial case was created.</p><p>OR: Odds ratio adjusted for age.</p></table-wrap-foot></table-wrap></p><p>The novel HPV 16 E6 variants were found in 11 women, 6 from the center of the State of Guerrero, 2 from the coast and 3 from Northern Guerrero. These variants were found in samples taken from 1997 to 2012. The AA-a/C188 HPV 16 variant was found in non-IL cervical sample taken in 1997, AA-c/G185 variant was found in a cervical carcinoma sample taken in 1998, E-A176/G424/G350 was found in a cervical carcinoma sample taken in 2003, E-C183/G350 was found in a non-IL cervical samples taken in 2002 and 2006, E-C306/G350 was found in non-IL a cervical sample taken in 2003, E-C188/G310/G350 was found in a non-IL cervical sample taken in 2004 and an LSIL taken in 2009, E-G535/G350 was found in an LSIL cervical sample taken in 2006 and E-G189/T256/G350 variant was found in an LSIL cervical sample taken in 2008. Six novel variants were found with non-IL, 3 with LSIL and 2 with cervical carcinoma (E-A176/G350/G424 and AA-c/G185). Data from a follow up cytological diagnosis of 5 women with HPV 16 E6 novel variants were collected. Follow up information shows that two with the variant E-C183/G350 evolved from non-IL to LSIL, whereas those with E-C188/G310/G350 and E-G189/T256/G350 maintain LSIL status (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Novel HPV16 E6 variants, regional distribution, collection year and lesion in cervical epithelium</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Patient</bold>
</th><th>
<bold>HPV 16 E6 Novel variant</bold>
</th><th>
<bold>Accession number GenBank</bold>
</th><th>
<bold>Nucleotide change</bold>
</th><th>
<bold>Amino acid change (not previously reported)</bold>
</th><th>
<bold>Women residence (City/State region)</bold>
</th><th>
<bold>Diagnosis/Sampling year</bold>
</th><th>
<bold>Follow up Diagnosis/Year</bold>
</th></tr></thead><tbody><tr valign="top"><td>1</td><td>E-A176/G424/G350</td><td>KJ465994</td><td>G424</td><td>-</td><td>Atoyac/Coast</td><td>Cervical carcinoma 2003</td><td>-</td></tr><tr valign="top"><td>2</td><td>E-C183/G350</td><td>KJ465995</td><td>C183</td><td>I27T</td><td>Chilpancingo/Center</td><td>Non-IL 2002</td><td>LSIL 2006</td></tr><tr valign="top"><td>3</td><td>E-C183/G350</td><td>KJ465995</td><td>C183</td><td>I27T</td><td>Chilpancingo/Center</td><td>Non-IL 2006</td><td>LSIL 2009</td></tr><tr valign="top"><td>4</td><td>E-C183/G350</td><td>KJ465995</td><td>C183</td><td>I27T</td><td>Chilpancingo/Center</td><td>Non-IL 2002</td><td>-</td></tr><tr valign="top"><td>5</td><td>E-C188/G310/G350</td><td>KJ465996</td><td>G310</td><td>-</td><td>Chilpancingo/Center</td><td>Non-IL 2004</td><td>Non-IL 2005</td></tr><tr valign="top"><td>6</td><td>E-C188/G310/G350</td><td>KJ465996</td><td>G310</td><td>-</td><td>Chilpancingo/Center</td><td>LSIL 2009</td><td>LSIL 2012</td></tr><tr valign="top"><td>7</td><td>E-G189/T256/G350</td><td>KJ465998</td><td>G189 and T256</td><td>-</td><td>Chilpancingo/Center</td><td>LSIL 2008</td><td>LSIL 2009</td></tr><tr valign="top"><td>8</td><td>E-C306/G350</td><td>KJ465997</td><td>C306</td><td>K68T</td><td>Acapulco Coast</td><td>Non-IL 2003</td><td>-</td></tr><tr valign="top"><td>9</td><td>E-G535/G350</td><td>KJ465999</td><td>G535</td><td>-</td><td>Tepecoacuilco/North</td><td>LSIL 2006</td><td>-</td></tr><tr valign="top"><td>10</td><td>AA-a/C188</td><td>KJ465992</td><td>C188</td><td>-</td><td>Iguala/North</td><td>Non-IL 1997</td><td>-</td></tr><tr valign="top"><td>11</td><td>AA-c/G185</td><td>KJ465993</td><td>G185</td><td>-</td><td>Juchitan/North</td><td>Cervical carcinoma 1998</td><td>-</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec5"><title>Sequence Data</title><p>The 8 novel variant sequences described in this report have been deposited in GenBank under designated accession numbers KJ465992, KJ465993, KJ465994, KJ465995, KJ465996, KJ465997, KJ465998 and KJ465999.</p></sec></sec><sec id="Sec6" sec-type="discussion"><title>Discussion</title><p>The objective of this study was to document HPV 16 E6 variants circulating over a period of 16&#x000a0;years in women from Southern Mexico and to analyze its association with cervical carcinoma and precursor lesions. According to sequence analysis, nucleotide polymorphisms were detected and used to investigate the intratypic heterogeneity of HPV 16 in the Southern Mexican population.</p><p>It is known that the genomes of HPV 16 variants differ geographically worldwide due to evolution linked to ethnic groups and that the risk for cervical carcinoma seems to be population-dependent [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR26">26</xref>-<xref ref-type="bibr" rid="CR28">28</xref>]. Mexico is a country with diverse ethnic origins because European immigrants mixed with various indigenous populations, in consequence current population carries HPV variant from various ethnic group [<xref ref-type="bibr" rid="CR8">8</xref>]. In the present study of 330 women with HPV 16 sampled over a period of 16&#x000a0;years, 27 variants were found; E variants were the most common, followed by AA variants. Studies worldwide have found that E variants are the most prevalent worldwide (94% in Oceania, 84% in Eastern Asia, 83% in North America, 82% in Europe, 78% in Western Asia and 71% in Central and South America) with exception of Africa (36%) [<xref ref-type="bibr" rid="CR9">9</xref>]. Tornesello, et al. (2011) showed that globally, the most prevalent variant in Central and South America (including Mexico) is E-G350 (43%) followed by AA (30%) and E-Prototype (27%). In North America it is E-Prototype and E-G350 (49% each one) followed by AA (11%). In Europe it is E-G350 (44%) followed by E-Prototype (38%) and AA (6%). In Western Asia it is E-G350 (51%) followed by E-Prototype (25%) and AA (9%). In Eastern Asia it is As (42%) followed by E-Prototype (37%) and E-G350 (9%). In Oceania it is E-Prototype (38%) followed by E-G350 (29%) and As (12%) and in Africa it is Afr1 and Afr2 (62%) followed by E-Prototype (34%). In the present study, the most frequently identified HPV 16 variant was E-G350 (40%), following the E-Prototype (13.03%), E-C188/G350 (11.82%), AA-a (10.61%), AA-c (6.07%) and E-A176/G350 (5.15%). However, unlike other regions, it was found that E-Prototype frequency in Southern Mexico is lower than the rest of the world, while E-G350, considering all its subclasses together, is more frequent than in the rest of the world. The AA variants of HPV 16 were 15-fold more prevalent than E-prototype in cervical carcinoma.</p><p>Studies on HPV 16 variants in Mexico have shown that even in the same country its distribution is different depending on the region analyzed. The prevalence of HPV 16 variants, stratified by histological groups, from five geographical regions of Mexico (Central, North-Central, Northeastern, Southeastern and Southern) is presented in Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>. The E variants are the most prevalent in all geographical regions in women, E-prototype in the Southeastern region and E-G350 in Central and Southern Mexico. AA variants are present in the five regions, but its prevalence is higher in the Northeastern region than in the rest of the country, although it is inhabited mostly by Europeans descendants, Mestizo and very few indigenous ethnic groups [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR29">29</xref>]. The State of Guerrero, located in Southern Mexico, is inhabited by Mestizo, Nahuas, Mixtecs, Amuzgos, Tlapanecos and Afro-Mexicans. In this study, which is larger than our previous study [<xref ref-type="bibr" rid="CR24">24</xref>], we found that HPV 16 E-G350 was the most common variant in all histological grades, although in ADC, the prevalence of E-G350 and AA is close. In all regions of Mexico, the prevalence of AA in ADC tends to increase in comparison to the other histological grades. Moreover, among AA variants, AA-a is more common than AA-c.<table-wrap id="Tab5"><label>Table 5</label><caption><p>
<bold>Published data on HPV 16 variants distribution in cervical epithelium lesions in regions of Mexico</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Region of Mexico</bold>
</th><th>
<bold>State/City</bold>
</th><th>
<bold>Genome region</bold>
</th><th>
<bold>Samples</bold>
</th><th>
<bold>Histology</bold>
</th><th>
<bold>HPV 16 E</bold>
</th><th>
<bold>HPV 16 E-Prototype</bold>
</th><th>
<bold>HPV 16 E-G350</bold>
</th><th>
<bold>AA</bold>
</th><th>
<bold>AA-a</bold>
</th><th>
<bold>AA-c</bold>
</th><th>
<bold>Reference</bold>
</th></tr></thead><tbody><tr valign="top"><td rowspan="3">Central</td><td rowspan="3">Mexico City</td><td rowspan="3">E6, L1</td><td>80</td><td>SCC</td><td>56%</td><td>4%</td><td>52%</td><td>44%</td><td>-</td><td>-</td><td rowspan="3">Berumen, et al., 2001</td></tr><tr valign="top"><td>6</td><td>ADC</td><td>0%</td><td>0%</td><td>0%</td><td>100%</td><td>-</td><td>-</td></tr><tr valign="top"><td>20</td><td>Non-IL</td><td>90%</td><td>5%</td><td>85%</td><td>10%</td><td>-</td><td>-</td></tr><tr valign="top"><td rowspan="5">Central</td><td rowspan="5">Mexico City</td><td rowspan="5">E6</td><td>50</td><td>SCC</td><td>30%</td><td>-</td><td>-</td><td>40%</td><td>32%</td><td>8%</td><td rowspan="5">Lizano, et al., 2006</td></tr><tr valign="top"><td>11</td><td>ADC</td><td>55%</td><td>-</td><td>-</td><td>45%</td><td>27%</td><td>18%</td></tr><tr valign="top"><td>23</td><td>HSIL</td><td>74%</td><td>-</td><td>-</td><td>26%</td><td>26%</td><td>0%</td></tr><tr valign="top"><td>13</td><td>LSIL</td><td>54%</td><td>-</td><td>-</td><td>46%</td><td>46%</td><td>0%</td></tr><tr valign="top"><td>16</td><td>Non-IL</td><td>56%</td><td>-</td><td>-</td><td>44%</td><td>44%</td><td>0%</td></tr><tr valign="top"><td rowspan="3">North-Central</td><td rowspan="3">San Luis Potos&#x000ed;</td><td rowspan="3">E6</td><td>2</td><td>ICC</td><td>100%</td><td>50%</td><td>50%</td><td>0%</td><td>0%</td><td>0%</td><td rowspan="3">L&#x000f3;pez-Revilla, et al., 2009</td></tr><tr valign="top"><td>9</td><td>HSIL</td><td>89%</td><td>33%</td><td>56%</td><td>11%</td><td>11%</td><td>0%</td></tr><tr valign="top"><td>27</td><td>LSIL</td><td>96%</td><td>85%</td><td>11%</td><td>4%</td><td>4%</td><td>0%</td></tr><tr valign="top"><td>Northeastern</td><td>Nuevo Le&#x000f3;n</td><td>LCR</td><td>112</td><td>Undefined</td><td>13%</td><td>-</td><td>-</td><td>87%</td><td>-</td><td>-</td><td>Calleja-Macias, et al., 2004</td></tr><tr valign="top"><td rowspan="2">Southeastern</td><td rowspan="2">Yucatan</td><td rowspan="2">E6</td><td>25</td><td>IIC</td><td>52%</td><td>28%</td><td>24%</td><td>44%</td><td>-</td><td>-</td><td rowspan="2">Gonz&#x000e1;lez-Losa, et al. 2004</td></tr><tr valign="top"><td>15</td><td>LSIL</td><td>100%</td><td>66%</td><td>33%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr valign="top"><td rowspan="4">Southern</td><td rowspan="4">Guerrero</td><td rowspan="4">E6</td><td>45</td><td>ICC</td><td>67%</td><td>-</td><td>-</td><td>33%</td><td>-</td><td>-</td><td rowspan="4">Illades-Aguiar, et al., 2010</td></tr><tr valign="top"><td>10</td><td>HSIL</td><td>90%</td><td>-</td><td>-</td><td>10%</td><td>-</td><td>-</td></tr><tr valign="top"><td>18</td><td>LSIL</td><td>67%</td><td>-</td><td>-</td><td>33%</td><td>-</td><td>-</td></tr><tr valign="top"><td>5</td><td>Non-IL</td><td>60%</td><td>-</td><td>-</td><td>40%</td><td>-</td><td>-</td></tr><tr valign="top"><td rowspan="5">Southern</td><td rowspan="5">Guerrero</td><td rowspan="5">E6</td><td>76</td><td>SCC</td><td>70%</td><td>3%</td><td>64%</td><td>30%</td><td>16%</td><td>14%</td><td/></tr><tr valign="top"><td>13</td><td>ADC</td><td>54%</td><td>-</td><td>54%</td><td>46%</td><td>38%</td><td>8%</td><td/></tr><tr valign="top"><td>19</td><td>HSIL</td><td>79%</td><td>5%</td><td>74%</td><td>21%</td><td>16%</td><td>5%</td><td rowspan="3">Present study</td></tr><tr valign="top"><td>123</td><td>LSIL</td><td>88%</td><td>19%</td><td>69%</td><td>11%</td><td>9%</td><td>2%</td></tr><tr valign="top"><td>97</td><td>Non-IL</td><td>90%</td><td>18%</td><td>66%</td><td>10%</td><td>4%</td><td>6%</td></tr></tbody></table></table-wrap></p><p>Of the 27 HPV 16 variants found in Southern Mexico in 16&#x000a0;years, 8 of them were new and may be considered to be variants specific to this Mexican region.</p><p>Previous data suggests that HPV 16 variants with E6 sequence variation are biologically distinct and may confer different pathological risks for development of squamous intraepithelial lesions and invasive cervical carcinoma. E6 specific sequence variations may modify its linkage to cellular targets changing its ability for p53 degradation, inhibiting keratynocyte differentiation, modifying signal transduction [<xref ref-type="bibr" rid="CR30">30</xref>-<xref ref-type="bibr" rid="CR34">34</xref>].</p><p>It was proposed that there might be a strong relation between AA variant and cervical carcinoma development [<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref>]. Using a comparative analysis, it was found in this study that HPV 16 AA-a detection rate increased according to the severity of the cervical lesion, with a large increase in ADC. The results show that HPV 16 AA-a infection has a strong association with a high risk of CC development compared to E-Prototype. This study reinforces the proposal that HPV 16 AA-a is an oncogenic risk for cervical carcinoma progression in Mexico [<xref ref-type="bibr" rid="CR5">5</xref>]. Similar behavior was observed in HPV 16 E-A176/G350 variant, the rate increased according severity of the cervical lesion, although frequency was less than for AA-a, and the infection is associated with a risk for development of CC compared with E-Prototype, but less than for AA-a. AA-c, E-G350 and E-C188/G350, also show association with risk for CC compared with E-Prototype, although lower than the aforementioned. The results of this study highlight the importance of identifying HPV 16 variants in the screening of clinical samples and of conducting follow up test for women with the HPV 16 AA-a variant.</p><p>According to the HPV variants found in this study, the amino acid substitutions circulating in Southern Mexico are: Q3E, R10G, Q14H, D25N, I27L, I27R I27T, L28V, E29K, E29Q, E29G, I52L, K68T, F69L, H78Y, L83V (the most frequent) and E113D. The amino acid substitutions present in the HPV 16 E6 variants in descending order of association with CC were: Q14R/H78Y/L83V (AA-a variant), D25N/L83V (E-A176/G350 variant), Q14R/I27/H78Y/L83V (AA-c variant), L83V (E-G350 variant) and E29Q/L83V (E-C188/G350 variant). Q14R/H78Y/L83V amino acid changes gender AA variants with increased oncogenic potential and more efficient evasion of the host&#x02019;s immune surveillance [<xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref>]. L83V amino acid change display more efficient degradation of Bax and binding to E6AP, induces ubiquitination and degradation of p53, NFX1-91 and PDZ proteins [<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR33">33</xref>]. D25N, I27R and E29Q amino acid changes affect E6 T cell epitope [<xref ref-type="bibr" rid="CR33">33</xref>]. Two of the 8 novel variants found in this study had amino acid changes not previously reported: I27T in E-C183/G350 variant and K68T in E-C306/G350 variant. I27T amino acid change is located at the N-terminal domain of the E6 oncoprotein; K68T is located between zinc fingers of E6. The E-C183/G350 variant was found in women with non-IL who progressed to LSIL. The finding of this new variant could be potentially important.</p><p>It was not possible to analyze the association of novel E6 variants for the risk of developing cervical carcinoma because of the low number of positive samples; however, by having nucleotide changes may also be associated with the development of cervical carcinoma.</p></sec><sec id="Sec7" sec-type="conclusion"><title>Conclusions</title><p>Current findings show that in 16&#x000a0;years, at least 27 HPV 16 E6 variants were present in Southern Mexico and 8 novel variants were found, which may be considered to be variants specific to this Mexican region. The variants more frequently found in women with cervical carcinoma are E-G350, AA-a, AA-c, E-C188/G350 and E-A176/G350. All of them are associated with the development of cervical carcinoma, however, AA-a showed the highest association. This study reinforces the proposal that HPV 16 AA-a is an oncogenic risk for cervical carcinoma progression in Mexico. This represents the largest study carried out in Mexico analyzing all classes of European and non-European variants in the whole spectrum of disease, from intraepithelial lesion-free cytology to cervical carcinoma including squamous cell carcinoma and adenocarcinoma. Further studies are needed to clarify the pathogenicity of HPV 16 E6 variants.</p></sec><sec id="Sec8" sec-type="materials|methods"><title>Methods</title><sec id="Sec9"><title>Samples</title><p>The database and biobank, with 7,480 cervical DNA samples collected from 1997 to 2012, of the Molecular Biomedicine and Cytopathology Laboratories at the School of Chemistry and Biology of the Autonomous University of Guerrero in Chilpancingo Guerrero, Mexico, was searched for all cervical DNA samples with HPV 16 and 330 were found in appropriate conditions for analysis. The samples were studied to investigate circulating HPV 16 variants in Southern Mexico and to do a comparative analysis between these variants and the different grades of cervical lesion.</p><p>Cervical samples came from women who were residents of State of Guerrero, seeking cytological screening or for other gynecological complaints, which attended public health centers of Acapulco, Chilpancingo, and Iguala, the three biggest cities in this state of Southern Mexico. Based on the diagnosis, samples were divided into: (1) no intraepithelial lesion (non-IL) (n&#x02009;=&#x02009;97), (2) low-grade squamous intraepithelial lesion (LSIL) (n&#x02009;=&#x02009;123), high-grade squamous intraepithelial lesion (HSIL) (n&#x02009;=&#x02009;19) and (4) cervical carcinoma (CC) (n&#x02009;=&#x02009;91). Non-IL and LSIL samples have cytological diagnosis; HSIL and CC samples have histological diagnosis. Cytological diagnosis was done according to the Bethesda System [<xref ref-type="bibr" rid="CR39">39</xref>] and histological diagnosis according to the classification system of the International Federation of Gynecology and Obstetrics (FIGO) [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p>This study was approved by the Bioethical Committee the Autonomous University of Guerrero. Informed consent was obtained from women participants.</p><p>HPV DNA was detected and identified by three methods depending on the year of in which the sample was taken and analyzed: (1) from 1997 to 2010, HPV detection was done by the MY09/11 system and typing by restriction fragment length polymorphism (RFLPs); (2) from 2005 to 2010, detection was done by general GP5+/6+ PCR system and typing by sequencing analysis [<xref ref-type="bibr" rid="CR24">24</xref>] when samples analyzed with MY09/11 PCR were negative; (3) from 2010 to 2012 HPV was detected and typed with INNO Lipa genotyping Extra (Innogenetics) [<xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="Sec10"><title>HPV variants</title><p>The HPV 16 E6 gene was amplified using type-specific primers E6-F048 (5&#x02032;GAACCGAAACCGGTTAGTAT3&#x02032;) and E6-R622 (5&#x02032;CAGTTGTCTCTGGTTGCAAA3&#x02032;) that amplify a 575-bp region [<xref ref-type="bibr" rid="CR19">19</xref>]. PCR amplification was carried out in a 50&#x000a0;&#x003bc;l reaction containing 1&#x000a0;&#x003bc;M of each primer, 4&#x000a0;mM of MgCl<sub>2</sub>, and 1.25 U of Platinum Taq DNA Polymerase (Invitrogen). The DNA amplification was done in a DNA Eppendorf AG 22331 Hamburg [<xref ref-type="bibr" rid="CR24">24</xref>] as follows: initial denaturation at 95&#x000b0;C for 10&#x000a0;min, followed by 40&#x000a0;cycles of 95&#x000b0;C for 45&#x000a0;s, 57&#x000b0;C for 30&#x000a0;s, 72&#x000b0;C for 1.15&#x000a0;min, and a final extension al 72&#x000b0;C for 10&#x000a0;min.</p><p>PCR products were purified with 75% isopropanol (2&#x02013;34 protocol of user manual of Applied Biosystems) and ZR DNA Sequencing Clean-up Kit&#x02122; (ZYMO RESEARCH). These were sequenced using Big Dye Terminator Chemistry v3.1 Ready Reaction Kit (Applied Biosystems, Foster City, CA) in an automated sequencer DNA ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA) using primers previously described [<xref ref-type="bibr" rid="CR19">19</xref>]. Sequences were analyzed with EMBOSS Stretcher of the European Institute of Bioinformatics, LALING GENESTREAM network server (<ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/Tools/psa/emboss_stretcher/nucleotide.html">http://www.ebi.ac.uk/Tools/psa/emboss_stretcher/nucleotide.html</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://embnet.vital-it.ch/software/LALIGN_form.html">http://embnet.vital-it.ch/software/LALIGN_form.html</ext-link>) and the Finch TV program respectively. Sequences were aligned with reference sequence (HPV 16R) [<xref ref-type="bibr" rid="CR8">8</xref>]. Using the E6 sequence, HPV 16 variants were classified into lineages with their respective sublineages [<xref ref-type="bibr" rid="CR12">12</xref>]. The sublineages were stratified in classes and subclasses [<xref ref-type="bibr" rid="CR13">13</xref>]. When new polymorphisms were found, independent PCRs were carried out under the described conditions. The products obtained were sequenced on both strands to exclude PCR artifacts and to validate the polymorphism found and accept them as new variants.</p></sec><sec id="Sec11"><title>Phylogenetic analysis</title><p>HPV 16 E6 sequences were compared by multiple sequence alignments using the CLUSTAL W method [<xref ref-type="bibr" rid="CR42">42</xref>]. A phylogenetic tree was constructed by neighbor-joining analysis executed by MEGA 5.2 program [<xref ref-type="bibr" rid="CR43">43</xref>].</p></sec><sec id="Sec12"><title>Statistical analysis</title><p>The Chi squared test was used to compare HPV 16 variant frequencies and cervical lesion grade. Differences were considered to be statistically significant when <italic>p</italic> values were less than 0.05. Age-adjusted odds ratios and 95% confidence intervals were used to estimate associations. Data analysis and statistics were done using IBM SPSS Statistics V.22.0 and STATA V.11 softwares.</p></sec></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>BIA and MALV designed and supervised research. JOO identified HPV 16, analyzed HPV 16 E6 variants, and did sequence alignment and statistical analysis. JOO, ICM did phylogenetic analysis. LCAR, MAJL and VHGB collected the samples and did cytological and histological diagnosis. JOO and BIA drafted the manuscript, HABS revised the manuscript and all authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Jos&#x000e9; Guadalupe Mu&#x000f1;oz Camacho and all of the Instituto Estatal de Cancerolog&#x000ed;a &#x0201c;Dr. Arturo Belt&#x000e1;n Ortega&#x0201d; who helped with this study at the clinic sites. We thank Miguel Angel Rodr&#x000ed;guez Barrera for his help in the registration of new variants in GenBank. We thank Dinorah N. Mart&#x000ed;nez-Carrillo for contributing in statistical analysis. We also thank Juan Francisco Leyva and Travis Ashworth for reviewing the English style of the article. This study was supported by grant from CONACYT, M&#x000e9;xico.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zur Hausen</surname><given-names>H</given-names></name></person-group><article-title>Papillomaviruses and cancer: from basic studies to clinical application</article-title><source>Nat Rev Cancer</source><year>2002</year><volume>2</volume><fpage>342</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1038/nrc798</pub-id><?supplied-pmid 12044010?><pub-id pub-id-type="pmid">12044010</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>P</given-names></name><name><surname>Howell-Jones</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Bruni</surname><given-names>L</given-names></name><name><surname>de Sanjose</surname><given-names>S</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Clifford</surname><given-names>GM</given-names></name></person-group><article-title>Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer</article-title><source>Int J Cancer</source><year>2012</year><volume>131</volume><fpage>2349</fpage><lpage>2359</lpage><pub-id pub-id-type="doi">10.1002/ijc.27485</pub-id><?supplied-pmid 22323075?><pub-id pub-id-type="pmid">22323075</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peitsaro</surname><given-names>P</given-names></name><name><surname>Johansson</surname><given-names>B</given-names></name><name><surname>Syrj&#x000e4;nen</surname><given-names>S</given-names></name></person-group><article-title>Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique</article-title><source>J Clin Microbiol</source><year>2002</year><volume>40</volume><issue>3</issue><fpage>886</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1128/JCM.40.3.886-891.2002</pub-id><?supplied-pmid 11880410?><pub-id pub-id-type="pmid">11880410</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gheit</surname><given-names>T</given-names></name><name><surname>Cornet</surname><given-names>I</given-names></name><name><surname>Clifford</surname><given-names>GM</given-names></name><name><surname>Iftner</surname><given-names>T</given-names></name><name><surname>Munk</surname><given-names>C</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name><name><surname>Kjaer</surname><given-names>SK</given-names></name></person-group><article-title>Risks for persistence and progression by human papillomavirus type 16 variant lineages among a population-based sample of Danish women</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2011</year><volume>20</volume><fpage>1315</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-10-1187</pub-id><?supplied-pmid 21527576?><pub-id pub-id-type="pmid">21527576</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berumen</surname><given-names>J</given-names></name><name><surname>Ordo&#x000f1;ez</surname><given-names>RM</given-names></name><name><surname>Lazcano</surname><given-names>E</given-names></name><name><surname>Salmer&#x000f3;n</surname><given-names>J</given-names></name><name><surname>Galv&#x000e1;n</surname><given-names>SC</given-names></name><name><surname>Estrada</surname><given-names>RA</given-names></name><name><surname>Yunes</surname><given-names>E</given-names></name><name><surname>Garc&#x000ed;a-Carranca</surname><given-names>A</given-names></name><name><surname>Gonzalez-Lira</surname><given-names>G</given-names></name><name><surname>Madrigal-de la Campa</surname><given-names>A</given-names></name></person-group><article-title>Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case&#x02013;control study</article-title><source>J Natl Cancer Inst</source><year>2001</year><volume>93</volume><issue>17</issue><fpage>1325</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1093/jnci/93.17.1325</pub-id><?supplied-pmid 11535707?><pub-id pub-id-type="pmid">11535707</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuna</surname><given-names>RE</given-names></name><name><surname>Moore</surname><given-names>WE</given-names></name><name><surname>Shanesmith</surname><given-names>RP</given-names></name><name><surname>Dunn</surname><given-names>ST</given-names></name><name><surname>Wang</surname><given-names>SS</given-names></name><name><surname>Schiffman</surname><given-names>M</given-names></name><name><surname>Blakey</surname><given-names>GI</given-names></name><name><surname>Teel</surname><given-names>T</given-names></name></person-group><article-title>Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population</article-title><source>Int J Cancer</source><year>2009</year><volume>125</volume><fpage>2609</fpage><lpage>2613</lpage><pub-id pub-id-type="doi">10.1002/ijc.24706</pub-id><?supplied-pmid 19569178?><pub-id pub-id-type="pmid">19569178</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffman</surname><given-names>M</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>AC</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Herrero</surname><given-names>R</given-names></name><name><surname>Hildesheim</surname><given-names>A</given-names></name><name><surname>Desalle</surname><given-names>R</given-names></name><name><surname>Befano</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Safaeian</surname><given-names>M</given-names></name><name><surname>Sherman</surname><given-names>ME</given-names></name><name><surname>Morales</surname><given-names>J</given-names></name><name><surname>Guillen</surname><given-names>D</given-names></name><name><surname>Alfaro</surname><given-names>M</given-names></name><name><surname>Hutchinson</surname><given-names>M</given-names></name><name><surname>Solomon</surname><given-names>D</given-names></name><name><surname>Castle</surname><given-names>PE</given-names></name><name><surname>Burk</surname><given-names>RD</given-names></name></person-group><article-title>A Population-Based Prospective Study of Carcinogenic Human Papillomavirus Variant Lineages, Viral Persistence, and Cervical Neoplasia</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><issue>8</issue><fpage>3159</fpage><lpage>3169</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-4179</pub-id><?supplied-pmid 20354192?><pub-id pub-id-type="pmid">20354192</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calleja-Mac&#x000ed;as</surname><given-names>IE</given-names></name><name><surname>Kalantari</surname><given-names>M</given-names></name><name><surname>Huh</surname><given-names>J</given-names></name><name><surname>Ortiz-L&#x000f3;pez</surname><given-names>R</given-names></name><name><surname>Rojas-Mart&#x000ed;nez</surname><given-names>A</given-names></name><name><surname>Gonzalez-Guerrero</surname><given-names>JF</given-names></name><name><surname>Williamson</surname><given-names>AL</given-names></name><name><surname>Hagmar</surname><given-names>B</given-names></name><name><surname>Wiley</surname><given-names>DJ</given-names></name><name><surname>Villarreal</surname><given-names>L</given-names></name><name><surname>Bernard</surname><given-names>HU</given-names></name><name><surname>Barrera-Salda&#x000f1;a</surname><given-names>HA</given-names></name></person-group><article-title>Genomic diversity of human papilomavirus- 16, 18, 31 and 35 isolates in a Mexican population and relationship to European, African, and Native American variants</article-title><source>Virol</source><year>2004</year><volume>319</volume><fpage>315</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2003.11.009</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tornesello</surname><given-names>ML</given-names></name><name><surname>Losito</surname><given-names>S</given-names></name><name><surname>Benincasa</surname><given-names>G</given-names></name><name><surname>Fulciniti</surname><given-names>F</given-names></name><name><surname>Botti</surname><given-names>G</given-names></name><name><surname>Greggi</surname><given-names>S</given-names></name><name><surname>Buonaguro</surname><given-names>L</given-names></name><name><surname>Buonaguro</surname><given-names>FM</given-names></name></person-group><article-title>Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix</article-title><source>Gynecol Oncol</source><year>2011</year><volume>121</volume><issue>1</issue><fpage>32</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2010.12.005</pub-id><?supplied-pmid 21211829?><pub-id pub-id-type="pmid">21211829</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornet</surname><given-names>I</given-names></name><name><surname>Gheit</surname><given-names>T</given-names></name><name><surname>Lannacone</surname><given-names>MR</given-names></name><name><surname>Vignat</surname><given-names>J</given-names></name><name><surname>Sylla</surname><given-names>BS</given-names></name><name><surname>Del Mistro</surname><given-names>A</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name><name><surname>Clifford</surname><given-names>GM</given-names></name><name><surname>IARC</surname><given-names>HPV</given-names></name><collab>Variant Study Group</collab></person-group><article-title>HPV16 genetic variation and the development of cervical cancer worldwide</article-title><source>Br J Cancer</source><year>2013</year><volume>108</volume><fpage>240</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1038/bjc.2012.508</pub-id><?supplied-pmid 23169278?><pub-id pub-id-type="pmid">23169278</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Schiffman</surname><given-names>M</given-names></name><name><surname>Herrero</surname><given-names>R</given-names></name><name><surname>De Salle</surname><given-names>R</given-names></name><name><surname>Anastos</surname><given-names>K</given-names></name><name><surname>Segondy</surname><given-names>M</given-names></name><name><surname>Sahasrabuddhe</surname><given-names>VV</given-names></name><name><surname>Gravitt</surname><given-names>PE</given-names></name><name><surname>Hsing</surname><given-names>AW</given-names></name><name><surname>Burk</surname><given-names>RD</given-names></name></person-group><article-title>Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67</article-title><source>Plos One</source><year>2011</year><volume>6</volume><issue>5</issue><fpage>e20183</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0020183</pub-id><?supplied-pmid 21673791?><pub-id pub-id-type="pmid">21673791</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornet</surname><given-names>I</given-names></name><name><surname>Gheit</surname><given-names>T</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Vignat</surname><given-names>J</given-names></name><name><surname>Burk</surname><given-names>RD</given-names></name><name><surname>Sylla</surname><given-names>BS</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name><name><surname>Clifford</surname><given-names>GM</given-names></name><collab>IARC HPV Variant Study Group</collab></person-group><article-title>Human Papillomavirus Type 16 Genetic Variants: Phylogeny and Classification Based on E6 and LCR</article-title><source>J Virol</source><year>2012</year><volume>86</volume><issue>12</issue><fpage>6855</fpage><lpage>6861</lpage><pub-id pub-id-type="doi">10.1128/JVI.00483-12</pub-id><?supplied-pmid 22491459?><pub-id pub-id-type="pmid">22491459</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huertas-Salgado</surname><given-names>A</given-names></name><name><surname>Mart&#x000ed;n-G&#x000e1;mez</surname><given-names>DC</given-names></name><name><surname>Moreno</surname><given-names>P</given-names></name><name><surname>Murillo</surname><given-names>R</given-names></name><name><surname>Bravo</surname><given-names>MM</given-names></name><name><surname>Villa</surname><given-names>L</given-names></name><name><surname>Molano</surname><given-names>M</given-names></name></person-group><article-title>E6 molecular variants of human papillomavirus (HPV) type 16: An updated and unified criterion for clustering and nomenclature</article-title><source>Virol</source><year>2011</year><volume>410</volume><issue>1</issue><fpage>201</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2010.10.039</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichtig</surname><given-names>H</given-names></name><name><surname>Algrisi</surname><given-names>M</given-names></name><name><surname>Botzer</surname><given-names>LE</given-names></name><name><surname>Abadi</surname><given-names>T</given-names></name><name><surname>Verbitzky</surname><given-names>Y</given-names></name><name><surname>Jackman</surname><given-names>A</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name><name><surname>Zehbe</surname><given-names>I</given-names></name><name><surname>Sherman</surname><given-names>L</given-names></name></person-group><article-title>HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6</article-title><source>Virol</source><year>2006</year><volume>350</volume><fpage>216</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.01.038</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehbe</surname><given-names>I</given-names></name><name><surname>Richard</surname><given-names>C</given-names></name><name><surname>Decarlo</surname><given-names>CA</given-names></name><name><surname>Shai</surname><given-names>A</given-names></name><name><surname>Lambert</surname><given-names>PF</given-names></name><name><surname>Lichtig</surname><given-names>H</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name><name><surname>Sherman</surname><given-names>L</given-names></name></person-group><article-title>Human papillomavirus 16 E6 variants differ in their dysregulation of humankeratinocyte differentiation and apoptosis</article-title><source>Virol</source><year>2009</year><volume>383</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2008.09.036</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehbe</surname><given-names>I</given-names></name><name><surname>Lichtig</surname><given-names>H</given-names></name><name><surname>Westerback</surname><given-names>A</given-names></name><name><surname>Lambert</surname><given-names>PF</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name><name><surname>Sherman</surname><given-names>L</given-names></name></person-group><article-title>Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential</article-title><source>Mol Cancer 2011</source><year>2011</year><volume>10</volume><issue>77</issue><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Reimers</surname><given-names>L</given-names></name><name><surname>Doorslaer</surname><given-names>K</given-names></name><name><surname>Schiffman</surname><given-names>M</given-names></name><name><surname>DeSalle</surname><given-names>R</given-names></name><name><surname>Herrero</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Burk</surname><given-names>RD</given-names></name></person-group><article-title>Sequence Imputation of HPV16 Genomes for Genetic Association Studies</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><issue>6</issue><fpage>e21375</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0021375</pub-id><?supplied-pmid 21731721?><pub-id pub-id-type="pmid">21731721</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>M</given-names></name><name><surname>Rhee</surname><given-names>JE</given-names></name><name><surname>Jang</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name></person-group><article-title>Gene Expression Profiles are Altered in Human Papillomavirus-16 E6 D25E-Expressing Cell Lines</article-title><source>Virol J</source><year>2011</year><volume>8</volume><issue>453</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21205327</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casas</surname><given-names>L</given-names></name><name><surname>Galv&#x000e1;n</surname><given-names>SC</given-names></name><name><surname>Ordo&#x000f1;ez</surname><given-names>RM</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>N</given-names></name><name><surname>Guido</surname><given-names>M</given-names></name><name><surname>Berumen</surname><given-names>J</given-names></name></person-group><article-title>Asian-american variants of human papillomavirus type 16 have extensive mutations in the E2 gene and are highly amplified in cervical carcinomas</article-title><source>Int J Cancer</source><year>1999</year><volume>83</volume><issue>4</issue><fpage>449</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19991112)83:4&#x0003c;449::AID-IJC3&#x0003e;3.0.CO;2-0</pub-id><?supplied-pmid 10508478?><pub-id pub-id-type="pmid">10508478</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lizano</surname><given-names>M</given-names></name><name><surname>Berumen</surname><given-names>J</given-names></name><name><surname>Garc&#x000ed;a-Carranca</surname><given-names>A</given-names></name></person-group><article-title>HPV-related Carcinogenesis: Basic Concepts, Viral Types and Variants</article-title><source>Arch Med Res</source><year>2009</year><volume>40</volume><issue>6</issue><fpage>428</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2009.06.001</pub-id><?supplied-pmid 19853182?><pub-id pub-id-type="pmid">19853182</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">L&#x000f3;pez-Revilla R, Pineda MA, Ort&#x000ed;z-Valdez J, S&#x000e1;nchez-Garza M, Riego L: Human papillomavirus type 16 variants in cervical intraepithelial neoplasia and invasive carcinoma in San Luis Potosi City, Mexico. Infectious Agents and Cancer 2009, <bold>4</bold>(3): <ext-link ext-link-type="uri" xlink:href="http://www.infectagentscancer.com/content/4/1/3">http://www.infectagentscancer.com/content/4/1/3</ext-link>.</mixed-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>CJ</given-names></name><name><surname>Given</surname><given-names>CW</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name></person-group><article-title>Health Care Disparities and Cervical Cancer</article-title><source>Am J Public Health</source><year>2004</year><volume>94</volume><issue>12</issue><fpage>2098</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.2105/AJPH.94.12.2098</pub-id><?supplied-pmid 15569960?><pub-id pub-id-type="pmid">15569960</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Secretar&#x000ed;a de Salud. Direcci&#x000f3;n General de Informaci&#x000f3;n en Salud. Mexico, 2006. Available from URL: <ext-link ext-link-type="uri" xlink:href="http://www.dgis.salud.gob.mx/descargas/xls/m_016.xls">http://www.dgis.salud.gob.mx/descargas/xls/m_016.xls</ext-link>. Accessed March 27, 2009.</mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illades-Aguiar</surname><given-names>B</given-names></name><name><surname>Alarc&#x000f3;n-Romero</surname><given-names>LC</given-names></name><name><surname>Antonio-V&#x000e9;jar</surname><given-names>V</given-names></name><name><surname>Zamudio-L&#x000f3;pez</surname><given-names>N</given-names></name><name><surname>Sales-Linares</surname><given-names>N</given-names></name><name><surname>Flores-Alfaro</surname><given-names>E</given-names></name><name><surname>Fern&#x000e1;ndez-Tilapa</surname><given-names>G</given-names></name><name><surname>Vences-Vel&#x000e1;zquez</surname><given-names>A</given-names></name><name><surname>Mu&#x000f1;oz-Valle</surname><given-names>JF</given-names></name><name><surname>Leyva-V&#x000e1;zquez</surname><given-names>MA</given-names></name></person-group><article-title>Prevalence and distribution of human papillomavirus types in cervical cancer, squamous intraepithelial lesions, and with no intraepithelial lesions in women from Southern Mexico</article-title><source>Gynecol Oncol</source><year>2010</year><volume>117</volume><issue>2</issue><fpage>291</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2010.01.036</pub-id><?supplied-pmid 20199804?><pub-id pub-id-type="pmid">20199804</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>C</given-names></name><name><surname>Lanner</surname><given-names>C</given-names></name><name><surname>Naryzhny</surname><given-names>SN</given-names></name><name><surname>Sherman</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Lambert</surname><given-names>PF</given-names></name><name><surname>Zehbe</surname><given-names>I</given-names></name></person-group><article-title>The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><issue>23</issue><fpage>3435</fpage><lpage>3445</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.93</pub-id><?supplied-pmid 20383192?><pub-id pub-id-type="pmid">20383192</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Manos</surname><given-names>MM</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name><name><surname>Greer</surname><given-names>C</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>N</given-names></name><name><surname>Bosh</surname><given-names>FX</given-names></name><name><surname>Wheeler</surname><given-names>M</given-names></name></person-group><article-title>Human papillomavirus type 16 sequence variation in cervical cancers: a wordlwide perspective</article-title><source>J Virol</source><year>1997</year><volume>71</volume><issue>3</issue><fpage>2463</fpage><lpage>2472</lpage><?supplied-pmid 9032384?><pub-id pub-id-type="pmid">9032384</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>LL</given-names></name><name><surname>Sichero</surname><given-names>L</given-names></name><name><surname>Rahal</surname><given-names>P</given-names></name><name><surname>Caballero</surname><given-names>O</given-names></name><name><surname>Ferenczy</surname><given-names>A</given-names></name><name><surname>Rohan</surname><given-names>T</given-names></name><name><surname>Franco</surname><given-names>EL</given-names></name></person-group><article-title>Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neopl&#x000e1;sica</article-title><source>J Gen Virol</source><year>2000</year><volume>81</volume><fpage>2959</fpage><lpage>2968</lpage><?supplied-pmid 11086127?><pub-id pub-id-type="pmid">11086127</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tornesello</surname><given-names>ML</given-names></name><name><surname>Duraturo</surname><given-names>ML</given-names></name><name><surname>Salatiello</surname><given-names>I</given-names></name><name><surname>Buonaguro</surname><given-names>L</given-names></name><name><surname>Losito</surname><given-names>S</given-names></name><name><surname>Botti</surname><given-names>G</given-names></name><name><surname>Stellato</surname><given-names>G</given-names></name><name><surname>Greggi</surname><given-names>S</given-names></name><name><surname>Piccoli</surname><given-names>R</given-names></name><name><surname>Pilotti</surname><given-names>S</given-names></name><name><surname>Stefanon</surname><given-names>B</given-names></name><name><surname>De Palo</surname><given-names>G</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Buobaguro</surname><given-names>FM</given-names></name></person-group><article-title>Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer</article-title><source>J Med Virol</source><year>2004</year><volume>74</volume><issue>1</issue><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1002/jmv.20154</pub-id><?supplied-pmid 15258977?><pub-id pub-id-type="pmid">15258977</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez-Losa</surname><given-names>MDR</given-names></name><name><surname>Laviada Mier y Teran</surname><given-names>MA</given-names></name><name><surname>Puerto-Sol&#x000ed;s</surname><given-names>M</given-names></name><name><surname>Garc&#x000ed;a-Carranc&#x000e1;</surname><given-names>A</given-names></name></person-group><article-title>Molecular variants of HPV type 16 E6 among Mexican women with LSIL and invasive cancer</article-title><source>J Clin Virol</source><year>2004</year><volume>29</volume><fpage>95</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/S1386-6532(03)00094-5</pub-id><pub-id pub-id-type="pmid">14747027</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehbe</surname><given-names>I</given-names></name><name><surname>Voglino</surname><given-names>G</given-names></name><name><surname>Wilander</surname><given-names>E</given-names></name><name><surname>Delius</surname><given-names>H</given-names></name><name><surname>Marongiu</surname><given-names>A</given-names></name><name><surname>Edler</surname><given-names>L</given-names></name><name><surname>Klimek</surname><given-names>F</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name></person-group><article-title>p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><issue>2</issue><fpage>608</fpage><lpage>611</lpage><?supplied-pmid 11212257?><pub-id pub-id-type="pmid">11212257</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>LF</given-names></name><name><surname>Koutsky</surname><given-names>LA</given-names></name><name><surname>Hildesheim</surname><given-names>A</given-names></name><name><surname>Galloway</surname><given-names>DA</given-names></name><name><surname>Wheeler</surname><given-names>CM</given-names></name><name><surname>Winer</surname><given-names>RL</given-names></name><name><surname>Ho</surname><given-names>J</given-names></name><name><surname>Kiviat</surname><given-names>NB</given-names></name></person-group><article-title>Risk for High-Grade Cervical Intraepithelial Neoplasia Associated with Variants of Human Papillomavirus Types 16 and 18</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2007</year><volume>16</volume><fpage>4</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-0670</pub-id><?supplied-pmid 17220325?><pub-id pub-id-type="pmid">17220325</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chopjitt</surname><given-names>P</given-names></name><name><surname>Ekalaksananan</surname><given-names>T</given-names></name><name><surname>Pientong</surname><given-names>C</given-names></name><name><surname>Kongyingyoes</surname><given-names>B</given-names></name><name><surname>Kleebkaow</surname><given-names>P</given-names></name><name><surname>Charoensri</surname><given-names>N</given-names></name></person-group><article-title>Prevalence of human papillomavirustype16 and its variants in abnormal squamous cervical cells in Northeast Thailand</article-title><source>Int J Infect Dis</source><year>2009</year><volume>13</volume><issue>2</issue><fpage>212</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2008.06.017</pub-id><?supplied-pmid 18838282?><pub-id pub-id-type="pmid">18838282</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>MR</given-names></name><name><surname>Hariharan</surname><given-names>R</given-names></name><name><surname>Babu</surname><given-names>JM</given-names></name><name><surname>Lakshmi</surname><given-names>S</given-names></name><name><surname>Chiplunkar</surname><given-names>SV</given-names></name><name><surname>Patkar</surname><given-names>M</given-names></name><name><surname>Tongaonkar</surname><given-names>H</given-names></name><name><surname>Dinshaw</surname><given-names>K</given-names></name><name><surname>Jayshree</surname><given-names>RS</given-names></name><name><surname>Reddy</surname><given-names>BK</given-names></name><name><surname>Siddiqui</surname><given-names>M</given-names></name><name><surname>Roychoudury</surname><given-names>S</given-names></name><name><surname>Saha</surname><given-names>B</given-names></name><name><surname>Abraham</surname><given-names>P</given-names></name><name><surname>Gnanamony</surname><given-names>M</given-names></name><name><surname>Peedicayil</surname><given-names>A</given-names></name><name><surname>Subhashini</surname><given-names>J</given-names></name><name><surname>Ram</surname><given-names>TS</given-names></name><name><surname>Dey</surname><given-names>B</given-names></name><name><surname>Sharma</surname><given-names>C</given-names></name><name><surname>Jain</surname><given-names>SK</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name></person-group><article-title>Molecular variants of HPV-16 associated with cervical cancer in Indian population</article-title><source>Int J Cancer</source><year>2009</year><volume>125</volume><issue>1</issue><fpage>91</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1002/ijc.24322</pub-id><?supplied-pmid 19358280?><pub-id pub-id-type="pmid">19358280</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wise-Draper</surname><given-names>TM</given-names></name><name><surname>Wells</surname><given-names>SL</given-names></name></person-group><article-title>Papillomavirus E6 and E7 proteins and their cellular targets</article-title><source>Front Biosci</source><year>2008</year><volume>13</volume><fpage>1003</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.2741/2739</pub-id><?supplied-pmid 17981607?><pub-id pub-id-type="pmid">17981607</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junes-Gill</surname><given-names>K</given-names></name><name><surname>Sichero</surname><given-names>L</given-names></name><name><surname>Maciag</surname><given-names>PC</given-names></name><name><surname>Mello</surname><given-names>W</given-names></name><name><surname>Noronha</surname><given-names>V</given-names></name><name><surname>Villa</surname><given-names>LL</given-names></name></person-group><article-title>Human papillomavirus type 16 variants in cervical cancer from an admixtured population in Brazil</article-title><source>J Med Virol</source><year>2008</year><volume>80</volume><fpage>1639</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1002/jmv.21238</pub-id><?supplied-pmid 18649325?><pub-id pub-id-type="pmid">18649325</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quint</surname><given-names>KD</given-names></name><name><surname>de Koning</surname><given-names>MN</given-names></name><name><surname>van Doorn</surname><given-names>LJ</given-names></name><name><surname>Quint</surname><given-names>WG</given-names></name><name><surname>Pirog</surname><given-names>EC</given-names></name></person-group><article-title>HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix</article-title><source>Gynecol Oncol</source><year>2010</year><volume>117</volume><issue>2</issue><fpage>297</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2010.02.003</pub-id><?supplied-pmid 20207397?><pub-id pub-id-type="pmid">20207397</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehbe</surname><given-names>I</given-names></name><name><surname>Mytilineos</surname><given-names>J</given-names></name><name><surname>Wikstr&#x000f6;m</surname><given-names>I</given-names></name><name><surname>Henriksen</surname><given-names>R</given-names></name><name><surname>Edler</surname><given-names>L</given-names></name><name><surname>Tommasino</surname><given-names>M</given-names></name></person-group><article-title>Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of swedish women</article-title><source>Hum Immunol</source><year>2003</year><volume>64</volume><issue>5</issue><fpage>538</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/S0198-8859(03)00033-8</pub-id><?supplied-pmid 12691704?><pub-id pub-id-type="pmid">12691704</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sichero</surname><given-names>L</given-names></name><name><surname>Sobrinho</surname><given-names>JS</given-names></name><name><surname>Villa</surname><given-names>LL</given-names></name></person-group><article-title>Oncogenic potential diverge among human papillomavirus type 16 natural variants</article-title><source>Virol</source><year>2012</year><volume>432</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2012.06.011</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>D</given-names></name><name><surname>Davey</surname><given-names>D</given-names></name><name><surname>Kurman</surname><given-names>R</given-names></name><name><surname>Moriarty</surname><given-names>A</given-names></name><name><surname>O'Connor</surname><given-names>D</given-names></name><name><surname>Prey</surname><given-names>M</given-names></name><name><surname>Raab</surname><given-names>S</given-names></name><name><surname>ShermanM</surname><given-names>W</given-names></name><name><surname>Wright</surname><given-names>TJ</given-names></name><name><surname>Young</surname><given-names>N</given-names></name></person-group><article-title>The 2001 Bethesda System: terminology for reporting results of cervical cytology</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>2114</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/jama.287.16.2114</pub-id><?supplied-pmid 11966386?><pub-id pub-id-type="pmid">11966386</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedet</surname><given-names>JL</given-names></name></person-group><article-title>FIGO staging classifications and clinical practice guidelines of gynaecologic cancers. FIGO Committee on Gynecologic Oncology</article-title><source>Int J Gynecol Obstet</source><year>2000</year><volume>70</volume><fpage>209</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/S0020-7292(00)90001-8</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleter</surname><given-names>B</given-names></name><name><surname>van Doorn</surname><given-names>LJ</given-names></name><name><surname>Schrauwen</surname><given-names>L</given-names></name><name><surname>Molijn</surname><given-names>A</given-names></name><name><surname>Sastrowijoto</surname><given-names>S</given-names></name><name><surname>ter Schegget</surname><given-names>J</given-names></name><name><surname>Lindeman</surname><given-names>J</given-names></name><name><surname>ter Harmsel</surname><given-names>B</given-names></name><name><surname>Burger</surname><given-names>M</given-names></name><name><surname>Quint</surname><given-names>W</given-names></name></person-group><article-title>Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus</article-title><source>J Clin Microbiol</source><year>1999</year><volume>37</volume><issue>8</issue><fpage>2508</fpage><lpage>17</lpage><?supplied-pmid 10405393?><pub-id pub-id-type="pmid">10405393</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>JD</given-names></name><name><surname>Gibson</surname><given-names>TJ</given-names></name><name><surname>Plewniak</surname><given-names>F</given-names></name><name><surname>Jeanmougin</surname><given-names>F</given-names></name><name><surname>Higgins</surname><given-names>DG</given-names></name></person-group><article-title>The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools</article-title><source>Nucleic Acids Res 1997</source><year>1997</year><volume>25</volume><issue>24</issue><fpage>4876</fpage><lpage>4882</lpage><pub-id pub-id-type="doi">10.1093/nar/25.24.4876</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Peterson</surname><given-names>D</given-names></name><name><surname>Peterson</surname><given-names>N</given-names></name><name><surname>Stecher</surname><given-names>G</given-names></name><name><surname>Nei</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>MEGA5: Molecular Evolutionary Genetics Analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods</article-title><source>Mol Biol Evol</source><year>2011</year><volume>28</volume><issue>10</issue><fpage>2731</fpage><lpage>2739</lpage><pub-id pub-id-type="doi">10.1093/molbev/msr121</pub-id><?supplied-pmid 21546353?><pub-id pub-id-type="pmid">21546353</pub-id></element-citation></ref></ref-list></back></article>